Clinical Trial Update: Adjuvant Docetaxel-Zoledronic Acid in High-risk Early Prostate Cancer Following Prostatectomy. [Phase 2]

View source ↗

Summary

Phase 2 trial of adjuvant docetaxel with zoledronic acid in high-risk early prostate cancer following prostatectomy was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Docetaxel (Taxotere) (docetaxel)
• Zoledronic acid (Zometa) (zoledronic acid)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Prostate Cancer | Phase 2 | Status: TERMINATED